Articles On Cann Group (ASX:CAN)
Title | Source | Codes | Date |
---|---|---|---|
How Bod Science pulled ahead in the race for Australia’s first over-the-counter CBD
Since TGA’s down-scheduling of CBD last year, no products have been sold in Australia But the race to market has been seemingly won by Bod Science following a ‘landmark update’ Stockhead reached out to BOD’s CEO, Jo Patterson Amidst gro... |
Stockhead | CAN | 1 year ago |
Cann Group doubles sales as Mildura cannabis crop set to triple
Medicinal cannabis company Cann Group (ASX: CAN) will start harvesting again from its Mildura facility in mid-July, with yields set to lift substantially after a financial year when sales more than doubled to reach $13.5 million, bolstered... |
businessnewsaustralia.com | CAN | 1 year ago |
Cann Group lights up medicinal cannabis market
Cann Group (ASX:CAN), a prominent player in the Australian medicinal cannabis industry, has announced its unaudited revenue results for the fiscal year 2023, showcasing remarkable growth. The company expects unaudited operating revenue of a... |
ShareCafe | CAN | 1 year ago |
Cann Group lights up medicinal cannabis market
05 Jul 2023 - Cann Group (ASX:CAN) has announced its unaudited revenue results for the fiscal year 2023, showcasing remarkable growth. |
FNN | CAN | 1 year ago |
ASX Health Stocks: Cann’s cannabis flower sales grow 500pc; Immuron runs out of Travelan as travel rebounds
Cann Group’s FY23 sales were 2.1 times that of FY22 Immuron’s FY23 sales increased by 136% from the previous year Cann Group doubles its sales revenue Cannabis house Cann Group (ASX:CAN) rose 8% this morning after releasing its full yea... |
Stockhead | CAN | 1 year ago |
Why ASX cannabis shares just jumped back into the spotlight
ASX cannabis shares have had a tough year. Thatâs despite the fact that the cannabis stocks operate in a country where medicinal marijuana is technically legal. Thatâs enabled them to provide valuable health services to many thousands... |
Motley Fool | CAN | 1 year ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | CAN | 1 year ago |
Weed Week: Storm before the calm as cannabis market set to boom after SAFE Banking Act passed
The weed industry has slumped as it faces several headwinds But new data suggests the industry will grow significantly over the next decade We take a look at how the ASX weed stocks have performed over the past week As we head into the... |
Stockhead | CAN | 1 year ago |
CLOSING BELL: Remember to say thanks to the techies, without whom we’d be deep in the red for the day
Local markets shook off a post-long-weekend wobble to end the day higher, up 0.23% It’s been another red-hot day for the techies, with that sector up by 3.7%. Health techie AHI went flying 370% this morning, and it’s anyone’s guess as to w... |
Stockhead | CAN | 1 year ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | CAN | 1 year ago |
Weed Week: A ‘shroom boom’ could see psychedelics follow cannabis’ explosive footsteps
The world is experiencing a ‘shroom boom’ Psychedelics are expected to follow in cannabis’ explosive footstep And here’s how the ASX weed stocks have performed, sorted by winners over the past week For years, people have frowned upon ps... |
Stockhead | CAN | 1 year ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | CAN | 1 year ago |
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight
Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week Earlier this week, Pfizer surprised the market by say... |
Stockhead | CAN | 1 year ago |
Weed Week: Cannabis helps chronic pain and insomnia, and here’s what the TGA rules say
Research in Australia shows marijuana helps with chronic pain and insomnia The rules around getting prescriptions for medicinal cannabis A quick look at the winners and losers of ASX weed stocks Sufferers of chronic pain and insomnia ha... |
Stockhead | CAN | 1 year ago |
Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?
The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit Medicare, telehealth and mental... |
Stockhead | CAN | 1 year ago |
Weed Week: New studies confirm cannabis alleviates cancer pain, cuts need for opioids, and improves sleep
Studies confirm that cannabis relieves pain in cancer patients In addition, cannabis also improves sleep and cognitive function in cancer patients We take a look at the biggest movers in ASX weed stocks over the past week It’s now offic... |
Stockhead | CAN | 1 year ago |
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | CAN | 1 year ago |
Weed Week: 420 reminds us that cannabis stocks may be down, but by no means out
The 420 Day is unofficially the World Marijuana Day, and we look at the possible origins of this day Cannabis stocks have been falling, but there’s still a lot of promise We take a look at the cannabis stocks on the ASX over the past week... |
Stockhead | CAN | 1 year ago |
Weed Week: Most Aussies still use illicit cannabis, but more are now turning to prescriptions
The number of Aussies using legal instead of illicit medical cannabis is rising The main reason for using prescribed medicinal cannabis was chronic pain, says Sydney Uni survey We take a look at what made the news in ASX weed stocks this p... |
Stockhead | CAN | 1 year ago |
WEED WEEK: Wellnex teams up with Chemist Warehouse for new cannabis products
Chemist Warehouse joins WNX JV to develop new cannabis products Neurotech launches new clinical program for its NTI164 drug in Rett Syndrome InhaleRx nabs approval for Phase 1 IRX211 clinical trial for Complex Regional Pain Syndrome Wel... |
Stockhead | CAN | 1 year ago |
Banking on pot: Minus one global investment house, Switzerland moves to legalise cannabis
The Swiss government has moved quickly to shore up its uniqueness as a centre of commerce – albeit one where the banks eat each other – and hurriedly green-lit (no pun) plans to legalise the sale and consumption of cannabis in Zurich, Switz... |
Stockhead | CAN | 1 year ago |
Buying ASX cannabis stocks? Here’s what the Victorian government is considering right now
ASX cannabis stocks provide a valuable service to the many thousands of Australians who benefit from the legal, medicinal benefits of their product. All told, the cannabis shares have grown, cured, and prepared medicinal marijuana products... |
Motley Fool | CAN | 1 year ago |
ASX Health Stocks: Most biotechs are still chasing maiden revenue, but here’s a few healthcare stocks with strong earnings
Alcidion increased sales significantly in the first half Cogstate sounds warning on outlook Probiotic had a super half Most biotech firms on the ASX are clinical stage companies, meaning they are still trying to prove that their drugs a... |
Stockhead | CAN | 1 year ago |
Weed Week: Musk gives the go-ahead for cannabis advertising on Twitter in the US
Twitter to allow cannabis companies to advertise in US states where it’s legal Elixnol comes out on top with CannaCare Health arbitration awarded in their favour Avecho expands CBD soft-gel capsule trials with the Lambert Initiative Twi... |
Stockhead | CAN | 1 year ago |
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry The US FDA announced last week that:... |
Stockhead | CAN | 1 year ago |
Weed Week: Codeine demand drops when recreational cannabis is legal, study finds
US States who allow recreational cannabis see less codeine demand WA GP wants Snoop Dogg to drop into parliament to chat cannabis reform Neurotech nabs pre-submission meeting with US FDA for CBD drug NTI164 A Cornell University study ha... |
Stockhead | CAN | 1 year ago |
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | CAN | 1 year ago |
C-Day invasion of Germany looks set and our Little Green Pharma already has boots on the ground
Germany: Next target for cannabis producers, huge market and could be live in 12 months Other Euro states about to legislate on industry in next few years Stockhead reached out to Little Green Pharma’s founder and CEO, Fleta Solomon Fol... |
Stockhead | CAN | 1 year ago |
Cann Group (ASX:CAN) appoints Peter Koetsier as new CEO
Cann Group (CAN) appoints Peter Koetsier as its new CEO following an extensive search process Mr Koetsier will replace Peter Crock, who announced that he would be stepping down as CEO of the company last October The incoming CEO has... |
themarketherald.com.au | CAN | 1 year ago |
Former AstraZeneca exec Peter Koetsier to lead Cann Group
Less than two months after announcing that Peter Crook would be stepping down as top boss, medicinal cannabis company Cann Group (ASX: CAN) has appointed Peter Koetsier as its new CEO from 16 January. The incoming executive held senior pos... |
businessnewsaustralia.com | CAN | 1 year ago |
Market Highlights: Fed comments scare the market, and 5 ASX small caps to watch on Tuesday
The ASX will open marginally lower on Tuesday Overnight, Wall Street was mixed but turned negative after comments from US Fed policymakers Oil prices rose another 1pc Aussie shares will open marginally lower this morning, and at 8am AED... |
Stockhead | CAN | 1 year ago |
Weed Week: Decriminalising cannabis could save Aussie tax payers billions every year
Penington Institute says pot-related law enforcement costs us $1.7 billion a year Local cannabis is missing out on international and domestic market opportunities Aussie medicinal cannabis revenue was around $230 million in 2021 Decri... |
Stockhead | CAN | 1 year ago |
ScoPo’s Powerplays: ASX healthcare sector Christmas rally runs out of puff
ASX Health sector has ended its upward trend falling 0.7% in the past five days in line with broader markets As the end of 2022 approaches several ASX health stocks announce capital raising results to secure funding Healius announces sal... |
Stockhead | CAN | 1 year ago |
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | CAN | 1 year ago |
Weed Week: More US states vote to legalise cannabis and Czech Republic to follow in Germany’s footsteps
Two more US states join the 19 that already allow legal recreational cannabis use ECS Botanics’ Victorian medical cannabis facility is safe from flooding in the state, so far Cann looks to commercialise its Satipharm CBD capsules for over-... |
Stockhead | CAN | 2 years ago |
Weed Week: Germany’s plans to legalise cannabis rekindle North American investment spark in Europe
Germany looks to legalise recreational cannabis and US and Canadian companies are paying attention Neurotech reports success with its cannabis-based drug for paediatric autism symptoms ECS Botanics has sold its Tasmanian business and a... |
Stockhead | CAN | 2 years ago |
Why Ampol, Cann, Reliance Worldwide, and South32 shares are dropping
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up 0.3% to 6,799.7 points. Four ASX shares that have failed to follow the market higher today are... |
Motley Fool | CAN | 2 years ago |
Peter Crock resigns as CEO of Cann Group (ASX:CAN)
Peter Crock resigns as CEO of Cann Group (CAN) but will remain in the position until a new CEO has been appointedSince joining Cann in May 2016, Mr Crock led the company through its IPO and helped raise $13.5 million to support it A search... |
themarketherald.com.au | CAN | 2 years ago |
Cann Group CEO leaves on a high
The man who led medicinal cannabis company Cann Group (ASX: CAN) through its 2017 initial public offering (IPO) is set to step down after six years in the role, leaving behind a legacy of three production sites including a flagship $115 mil... |
businessnewsaustralia.com | CAN | 2 years ago |
Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities?
We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month There were 191 ASX IPOs in... |
Stockhead | CAN | 2 years ago |
Why is everyone talking about ASX cannabis shares all of a sudden?
ASX cannabis shares have leapt back onto investor radars and are likely to grab more media headlines in the weeks ahead. While all three are deep in the red today amid wider selling action that sees the All Ordinaries Index (ASX: XAO) down... |
Motley Fool | CAN | 2 years ago |
ASX moves lower amidst fears of another Fed rate hike: Aus shares 0.6% down at noon
ShareCafeASX moves lower amidst fears of another Fed rate hike: Aus shares 0.6% down at noon by Peter Milios At noon, S&P/ASX 200 is 0.61 per cent or 41.90 points lower at 6775.60, following a tumultuous day in the US markets, as the... |
ShareCafe | CAN | 2 years ago |
Stocks of the Hour: TBN, KGD
ShareCafeStocks of the Hour: TBN, KGD Cannabis stocks were the highlight overnight as President Joe Biden pardoned all prior federal offences of simple marijuana possession. This has flowed through to medicinal cann... |
ShareCafe | CAN | 2 years ago |
Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice
Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re... |
Stockhead | CAN | 2 years ago |
Weed Week: The lazy stoner stereotype is a myth and this Aussie uni wants to study home grown cannabis
Cambridge says cannabis smokers are not actually lazy, that’s a myth USyd wants to test home-grown cannabis in the ACT Incannex joins the big leagues S&P/ASX300 index It turns out that the lazy stoner stereotype is actually a myth,... |
Stockhead | CAN | 2 years ago |
Weed Week: Legal use of medicinal cannabis in Australia on the rise, Lambert Initiative says
Researchers say data shows transition from illicit to legal use of cannabis Medicinal users are at 37%, compared to 2.5% in 2018 Regulations, quality control and costs still barriers for legal week users New research from the University... |
Stockhead | CAN | 2 years ago |
Can ASX cannabis shares ever fully recover?
ASX cannabis shares have been mixed performers on the market in the year to date, but are there better days ahead? Cannabis shares on the ASX include Cronos Australia Ltd (ASX: CAU), Incannex Healthcare Ltd (ASX: IHL), Emyria Ltd (ASX: E... |
Motley Fool | CAN | 2 years ago |
Weed Week: Ice-T plans to open dispensary and Snoop Dogg’s venture capital firm backs weed snacks
Ice-T is opening a cannabis dispensary in New Jersey this year Snoop Dogg’s venture capital firm led a seed funding round for TSUMo Snacks Incannex ramps up development and manufacturing of IHL-216A drug New Jersey has given Ice-T the gre... |
Stockhead | CAN | 2 years ago |
Weed Week: Aurora Marijuanis and CBD bubble tea in Thailand
Mysterious pink glow over Mildura Thailand businesses go nuts for CBD desserts and bubble tea ECS nabs $2m commercial loan facility to invest in new capacity ICYMI a mysterious pink glow above Mildura sent residents into a bit of a frenzy... |
Stockhead | CAN | 2 years ago |
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F... |
Stockhead | CAN | 2 years ago |